JANX
Janux Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.19 / 10
Netural
Janux Therapeutics shows moderate fundamental strength (score 4.2/10). Key positives include a healthy interest-coverage ratio (15.48) and solid asset-to-market value alignment. However, concerns linger over days-sales-outstanding (72.55) and negative year-over-year revenue growth (-5.55%). These mixed signals justify a constrained investment posture.
Analysis Checks(9/10)
Revenue-MV
Value-2.96
Score3/3
Weight18.76%
1M Return10.54%
Value-2.96
Score3/3
Weight18.76%
1M Return10.54%
Days sales outstanding
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Net income-Revenue
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Asset-MV
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Total operating revenue (YoY growth rate %)
Value-5.55
Score2/3
Weight1.60%
1M Return1.11%
Value-5.55
Score2/3
Weight1.60%
1M Return1.11%
Profit-MV
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
PB-ROE
Value0.36
Score2/3
Weight18.65%
1M Return9.14%
Value0.36
Score2/3
Weight18.65%
1M Return9.14%
Operating revenue (YoY growth rate %)
Value-5.55
Score2/3
Weight0.62%
1M Return0.43%
Value-5.55
Score2/3
Weight0.62%
1M Return0.43%
Cash-MV
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Revenue-MV
Value-2.96
Score3/3
Weight18.76%
1M Return10.54%
Value-2.96
Score3/3
Weight18.76%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value-5.55
Score2/3
Weight1.60%
1M Return1.11%
Value-5.55
Score2/3
Weight1.60%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Value72.55
Score1/3
Weight-2.06%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
Value0.46
Score2/3
Weight14.96%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
Value-0.17
Score2/3
Weight14.97%
1M Return8.45%
PB-ROE
Value0.36
Score2/3
Weight18.65%
1M Return9.14%
Value0.36
Score2/3
Weight18.65%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Value15.48
Score2/3
Weight-1.50%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-5.55
Score2/3
Weight0.62%
1M Return0.43%
Value-5.55
Score2/3
Weight0.62%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Value-0.50
Score2/3
Weight19.29%
1M Return10.15%
Cash-MV
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Value-0.07
Score2/3
Weight14.71%
1M Return8.41%
Is JANX undervalued or overvalued?
- JANX scores 4.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -8.17% ROE, -1018.95% net margin, -7.44 P/E ratio, 0.81 P/B ratio, and -42.74% earnings growth, these metrics solidify its Netural investment rating.
